Aimmune Therapeutics, Inc. announced that the European Commission has approved PALFORZIA [defatted powder of Arachis hypogaea L., semen (peanuts)] for the treatment of peanut allergy. PALFORZIA is indicated in patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy in conjunction with a peanut-avoidant diet and may be continued in patients 18 years of age and older. The approval was based on a package of data including two pivotal Phase 3 clinical trials, PALISADE and ARTEMIS. In both studies, PALFORZIA treatment resulted in a significant increase in the amount of peanut protein tolerated, compared to placebo.